SALAMA

We are the RISK lens: we score breaks: ocf_to_ni < 0.7, net_debt_to_ebitda > 4, ebitda_interest_cover < 2, liquidity.advv_30d_aed_m < 1, quarterly_gaps, dividend cut. We output a graded verdict. We need to assess SALAMA. First, extract figures: - ocf_to_ni: from financial_statements.derived.ocf_to_ni = -5.16. That's < 0.7, so BREAK. - net_debt_to_ebitda: We don't have exactly that. But we have debt_to_equity = 0.012, which is low, and total_liabilities = 2876.1, total_assets = 3236.1, equity = 360.0. Net debt? Cash = 193.8. Interest-bearing debt? Possibly none from debt_to_equity 0.012. So net_debt_to_ebitda likely not >4. We don't have EBITDA either, but with minimal debt, probably no break. - ebitda_interest_cover: no EBITDA or interest expense given. But with low debt, unlikely <2. - liquidity.advv_30d_aed_m = 5.1032. That's > 1, so no break. - quarterly_gaps: present: "no quarter between 2024-12-31 and 2025-06-30". So there is a gap. That is a break (since condition is "quarterly_gaps present"). - dividend cut: dividend_yield = 0.0, and corporate actions show last dividend in 2022 (2% cash). Since then, no dividends. Recent news: "SALAMA reports net profit of AED 14 mn in Q1 2026" and capital raise. No indication of dividend reinstatement. dividend_yield is 0, indicating no dividend. So there is a cut (from prior dividends to zero). The condition "dividend cut evident in financial_statements" could refer to dividends paid. In annual data, we see dividends_paid for 2022: -23.7, but for later years no dividends_paid field. The derived dividend_yield is 0, so dividend cut is evident. So break? But careful: the condition says "dividend cut evident in financial_statements". Financial_statements show zero dividends in recent periods. So yes, break. So we have breaks: ocf_to_ni (-5.16), quarterly_gaps present, dividend cut. That's at least 2 breaks. So should be SELL. But we must also check if any offsetting factors. The stance: 0 breaks -> BUY is legit; 1 break -> HOLD unless offset; 2+ cited breaks -> SELL. So SELL. We need to cite exact figures. So cite: - financial_statements.derived.ocf_to_ni: -5.16 - financial_statements.quarterly_gaps.0: "no quarter between 2024-12-31 and 2025-06-30" - fundamentals.dividend_yield: 0.0 (but maybe need to show cut: corporate_actions show dividends historically and now zero. We can cite fundamentals.dividend_yield as 0, indicating no dividend, and perhaps corporate_actions.history.0.type "Cash Dividends" with year 2022 as last dividend. But condition says "dividend cut evident in financial_statements". In financial_statements, we see no dividend after 2022. In annual data, 2025, 2024 no dividends_paid. So we can cite financial_statements.annual.0.period "2025-12-31" with no dividends_paid field? Actually the data doesn't include dividends_paid for those years. But we have corporate_actions showing dividends up to 2022 and then nothing. And fundamentals.dividend_yield 0. So we'll cite fundamentals.dividend_yield: 0.0 and maybe corporate_actions as evidence of prior dividends. But the citation should be from the pack fields. We'll use fundamentals.dividend_yield: 0.0 as the field that shows no dividend now. We need to output point and risk. point: one sentence citing a figure. risk: one line. stance: SELL. confidence: we need to assign based on alignment. Breaks are multiple. Confidence bands: 90-100 if multiple independent cited figures align AND a dated catalyst inside horizon. There is a dated catalyst? The horizon is 4 weeks ending 2026-08-17. Recent disclosures: some board meetings, appointment of CFO, press releases. No specific dated catalyst like earnings date inside horizon. The last results filing was for Q1 2026 on 2026-05-18. The next might be Q2 2026, but not dated. So no dated catalyst. So confidence falls to 70-89 if several aligned cited figures, no dated catalyst. We have 3 breaks aligned. So confidence 70-89. But we must check if there's any offsetting. The recent news is positive about capital raise and Q1 profit, but our lens is on risk breaks. So confidence around 80 maybe. We'll pick 80. But also note that the stock rose significantly: ret_1m_pct 14.98%, rsi14 64.6, so momentum is positive, but our risk lens is about fundamental breaks. So confidence might be tempered, but we'll stick with high because multiple independent breaks. However, the breaks: ocf_to_ni is negative, quarterly gaps, dividend cut. These are strong signals. So confidence 75? That's within 70-89. I'll set 75. But to be precise, 75 is fine. Target: we need to derive from pack evidence for 4-week horizon. Not analyst target_mean (null anyway). We might infer a target for downside. The risk lens, when SELL, might estimate a target. But given the massive run-up (ret_3m_pct 64%), and the breaks, it could correct. But we don't have a specific target. The output can be null if not derivable. The instruction: "If you output a target, derive it from pack evidence for the 4-week horizon — do not restate analyst.target_mean (a 12-month figure) as your own target." Since we don't have a clear target from fundamentals, we might set null. But we could use technicals like pct_below_52w_high: 8.19% below high, so maybe target at support? Not straightforward. I'll set target null. citations: list exact pack fields and values. At least 2 for non-HOLD. So: - financial_statements.derived.ocf_to_ni: -5.16 - financial_statements.quarterly_gaps.0: "no quarter between 2024-12-31 and 2025-06-30" - fundamentals.dividend_yield: 0.0 (or could cite corporate_actions.history.0.year 2022 as last dividend, but we need to show cut. Using dividend_yield 0 shows current no dividend. Also, we can cite fundamentals.dividend_yield: 0.0 as the field that shows no dividend. That's a direct pack field.) So three citations. Now, point: one sentence citing a figure. For risk lens, point might be: "Operating cash flow to net income stands at -5.16, far below the 0.7 threshold, indicating severe accrual-heavy earnings." risk: one line. Something like: "Multiple red flags: negative OCF/NI, missing quarterly filings, and suspended dividends signal capital-preservation alert." stance: SELL confidence: 75 target: null Output JSON in order.

We are the MACRO-LIQUIDITY lens. Our job is cross-sectional: the peg and Fed rate are identical for all 61 DFM names, so we cannot justify a stance on SALAMA based solely on those. We must cite which of this name's own figures makes it more or less exposed to the macro backdrop than the market. We need to consider fundamentals.debt_to_equity (rate sensitivity), tv_technicals.beta_1y, liquidity.advv_30d_aed_m (flow sensitivity), sector, peer_context percentiles. We'll cite macro.fed_funds_rate / macro.vix / macro.yield_curve_2s10s_pct for the backdrop AND the differentiating name-level figure. Weigh uae_macro_news where present. Today is 2026-07-20, horizon ends 2026-08-17 (4-week). We must output JSON with keys: citations, point, risk, stance, confidence, target. First, the macro backdrop: fed_funds_rate=3.63%, vix=16.73, yield_curve_2s10s_pct=0.37% (slightly positively sloped, but steepness?). The yield curve is not deeply inverted; actually positive 0.37%. That might indicate normalizing conditions? But 3.63% Fed rate is still relatively high? Actually, the Fed funds rate is moderate. The VIX at 16.73 is not high, indicating low volatility. That could be supportive for risk assets, but we need to see how SALAMA is sensitive. SALAMA: Fundamentals debt_to_equity is 0.012 (very low). That means minimal interest rate sensitivity from debt. So rate movements shouldn't impact much. But insurance companies might have large investment portfolios that are rate-sensitive. However, the debt_to_equity ratio specifically measures financial leverage, not investment portfolio sensitivity. So low debt_to_equity means low rate sensitivity from debt financing. Beta_1y: 0.8101. That's below 1, meaning it's less volatile than the market. So from a macro sensitivity standpoint, it's less exposed to broad market swings. Liquidity: advv_30d_aed_m is 5.1032. We need to compare to market median? Not directly provided, but we can check if that's low or high. Given market cap ~701M AED, 5.1M AED daily turnover is about 0.73% of market cap. That might be moderate. But in the peer context, we have universe_n=61, median PE, PB, div yield, but no median liquidity. However, low liquidity can make it vulnerable to macro shocks if outflows happen, but also it might be less liquid. Sector: Financial Services. Insurance is part of that. Peer context: PE percentile 89 (high relative PE), meaning it's expensive relative to peers. Dividend yield percentile 31, meaning below median dividend yield. So it's not attractive for income. Now, macro backdrop: Fed rate at 3.63% is not extremely high or low. VIX low. Yield curve slightly positive. Overall, benign macro. But we need to see if SALAMA's figures make it more or less exposed. Low debt/equity and beta below 1 suggest less sensitivity. So it should be relatively insulated from macro volatility. But also, a low beta stock in a benign macro might underperform if risk-on sentiment favors high beta. However, our horizon is only 4 weeks, and we need a stance. As macro-liquidity lens, we look at how macro moves might impact it relative to others. Given low beta, it might be a defensive play if macro turns sour, but right now macro seems stable. The VIX is not elevated. The uae_macro_news includes positive items like Emiratization surpassing 190k, Jaywan payment scheme launch, but also a Houthi naval embargo against Saudi Arabia which could raise geopolitical risk. That might impact UAE markets? Possibly negative for sentiment. But the DFMGI has returned -5.958% over 1 month, and -1.19% over 3 months, while SALAMA returned +14.98% 1-month and +64.16% 3-month. So it has massively outperformed the market recently. That could be due to company-specific factors (e.g., capital raise, record profits) rather than macro. As macro-liquidity, we might see that if macro headwinds arise, this stock's high recent returns might make it vulnerable to profit-taking, or its low beta might protect it. But the relative strength 3m vs DFMGI is +58.98%, showing strong outperformance. We also have consensus_signal_drift: tv_recommend_all 0.2424, delta_5d -0.294, delta_10d -0.361, indicating negative drift in technical recommendation. That might signal weakening momentum. Now, to build a case: The macro backdrop of low VIX and slightly positive yield curve suggests a generally supportive environment for equities, but SALAMA's low beta (0.81) and extremely low debt/equity (0.012) mean it is less macro-sensitive than peers, so it might not benefit as much from macro-driven rallies. Conversely, if there is a macro shock, it might hold up better. But the recent strong performance might be overextended. Given the negative drift in technical consensus and the relative high PE compared to peers, the stock may be priced for continued good news. The uae_macro_news includes a potential geopolitical risk (Houthi embargo), which could spook markets, but SALAMA's low beta could mitigate downside. However, its liquidity (ADVV 5.1M AED) might be a concern if large sellers emerge; flow sensitivity could be high if institutional investors reduce risk. We need a stance. Our confidence requirement: non-HOLD needs at least 2 citations. We'll aim for HOLD, SELL, or BUY. As macro-liquidity, we might lean HOLD because the stock's low sensitivity means macro isn't a strong driver either way. But let's see if we can make a case for SELL based on overvaluation and potential macro headwinds, or BUY based on defensiveness. Given the low VIX, that's not a defensive setup. The yield curve isn't flashing recession. So macro is neutral-positive. The stock's own figures: high PE percentile (89) suggests it's expensive relative to sector, which could be a drag if macro liquidity tightens (though Fed rate is moderate). But its debt/equity is low, so less rate sensitivity. The low beta might make it a safe haven if geopolitical risks rise. But the recent huge run-up might be unsustainable. We might output HOLD with moderate confidence. To get confidence above 40, we need some alignment. We'll cite figures indicating low macro sensitivity: debt_to_equity 0.012, beta 0.81, and perhaps the high PE percentile as a risk, but that's not macro differentiation. We'll say: "With low debt/equity (0.012) and beta (0.81), SALAMA is less exposed to macro moves than the DFM universe; combined with benign VIX (16.73) and modest yield curve slope (0.37%), macro forces are not decisive, but negative technical consensus drift (-0.361 over 10d) and overbought levels after +64% 3-m return suggest limited near-term upside, warranting HOLD." That might work. Confidence: maybe 50-69? Since no dated catalyst inside horizon. Last results filing was 2026-05-18 for Q1 2026, which is already behind. Next catalyst? Possibly Q2 results, but not within our horizon? The 24-month results filing dates show pattern: Q1 FY2026 filed 2026-05-18, FY2025 filed 2026-03-27, Q3 2025 filed 2025-11-12. So Q2 2026 would likely be filed around August 2026? The horizon ends Aug 17. Could be within? But no disclosure of a dated catalyst. So confidence band 70-89 requires dated catalyst; we don't have it. So we'll be in 50-69 or lower. But we have clear evidence with real conflicts: low macro sensitivity vs high relative valuation and negative technical drift. So confidence 55. We need target: derive from pack evidence for 4-week. Not given analyst target. We might use technicals or recent price action. Spot is 0.852. Recent 1m return +15%, 3m +64%, so it's extended. RSI 64.6, not overbought yet. Pct off 20d high -3.18%, so near high. We could set a target around current or slightly lower? Since stance HOLD, target could be near spot, maybe 0.85, or no target? For HOLD, we can output target as null or a slight range. But the instruction: "if you output a target, derive it..." For HOLD, target is optional. I'll set target to null. Risk: something like "Geopolitical flare-up from Houthi embargo could weigh on UAE risk assets, potentially hurting SALAMA's liquidity despite its low beta." Point: "SALAMA's low debt-to-equity (0.012) and 1-year beta (0.81) make it less macro-sensitive than peers, suggesting macro backdrop of low VIX (16.73) and positive yield curve (0.37%) is not a strong differentiator, while negative technical consensus drift (-0.361 over 10d) and high PE percentile (89) raise near-term caution." Citations: We'll cite debt_to_equity, beta_1y, advv_30d_aed_m (maybe), vix, yield_curve, pe_percentile, consensus_drift. Need at least 2 for non-HOLD, but our stance is HOLD, so it's okay. We'll include a few. Order: citations array, point string, risk string, stance string, confidence number, target null. Now, output JSON only.

We are asked to output a JSON object for SALAMA. Key: stance covers 4-week horizon ending 2026-08-17. Today is 2026-07-20. We are the SECTOR specialist, focusing on business economics, growth, margins, leverage, dividend durability. Must reason over the evidence pack, cite exact figures. Need to consider fundamentals, analyst consensus, recent disclosures/news, technicals relevant to lens. Output includes citations, point, risk, stance, confidence, target (if any). First, review the pack. SALAMA is in Financial Services, insurance sector. The data: fundamentals: pe_ttm 30.5376, pb 0.6805, ps 0.3426, roe 4.3178, roa 0.4964, operating_margin 1.9512, net_margin 1.4676, rev_growth_yoy -10.5117, eps_growth_yoy 564.2857 (but from a small base), debt_to_equity 0.012, current_ratio 4.1001, dividend_yield 0.0. Market cap 701m AED. Financial statements: annual periods up to 2025-12-31. Revenue: 2025: 1005m, 2024: 1046.4m, 2023: 1111m, 2022: 924.1m. Net income: 2025: 11.2m, 2024: 24.6m, net margin: 1.1% and 2.4% respectively. OCF negative in 2025: -57.8m, 2024: -77.4m. FCF negative. Equity: 360m in 2025, 334.4m in 2024. Liabilities to equity: 7.99 in 2025, 8.89 in 2024. The trend: revenue declining from 2023 peak (1111m) to 1005m in 2025, net income halved from 24.6m to 11.2m. Margins thin and declining. ROE low (3.1% derived). Dividend yield 0%, no recent dividends (last in 2022). Quarterly: 2025 Q4 (derived): revenue 236.3m, net income 0.1m, margin 0%; Q3: rev 253.4m, NI 2.8m, margin 1.1%; Q2: rev 259m, NI 7.9m, margin 3.1%. So profitability deteriorated sharply in Q4. Q1 2026 results not in quarterly list, but recent news: "SALAMA reports net profit of AED 14 mn in Q1 2026" (headline from 2026-05-19). That indicates significant improvement over prior quarters? 14m net profit in Q1 2026 vs. Q4 2025 net income 0.1m. So that's a positive sign. Also recent disclosures: 2026-05-18 press release regarding financial results for Q1 2026. Also capital increase activation, board leadership appointments. Peer context: SALAMA's PE ttm 30.5 vs. median 11.32, percentile 89 - very expensive relative to peers. PB 0.68 vs. median 1.35, so undervalued on book, but that might be due to low ROE. Dividend yield 0% vs. median 4.55%, no income support. Technicals: Price 0.852. Indicators: rsi14 64.6 (near overbought), pct_vs_ma200 52.3%, ret_1m_pct +15%, ret_3m_pct +64%, so strong recent momentum. However, tv_recommend_all 0.2424 (slight buy), but tv_recommend_delta_5d -0.294, delta_10d -0.361, indicating recent deterioration in consensus signal. Technicals show adx 52.2857 (trending), cci20 63.6, stoch_k 59.8, williams_r -47.8, all neutral-ish. From a sector perspective: SALAMA's margins are razor-thin, with net margin 1.47% TTM, and declining trend. Revenue growth negative. The recent Q1 2026 profit of 14m AED might be a turnaround, but only one quarter. Positive catalysts: capital increase, strategic investor Mandatory Convertible Sukuk approval, which might strengthen equity and solvency. But over 4 weeks, the immediate catalyst could be the Q1 results published May 18, but that's already past. Upcoming: no specific dated catalyst mentioned within the horizon (4 weeks from Jul 20 to Aug 17). There could be board meeting outcomes, but no filings scheduled. The horizon ends before likely next quarterly (Q2 would be mid-August?). From recent filings: Q1 filed 2026-05-18, so Q2 might be due around August? But no scheduled date in pack. So no dated catalyst in horizon. Confidence bands: 90-100 = multiple independent cited figures align AND a dated catalyst inside horizon. There is no dated catalyst, so max confidence might be 70-89 if several aligned cited figures. But are they aligned? Opinions: On one hand, Q1 profit jump (14m vs previous year's Q1 17.6m? Actually Q1 2024 was 17.6m, so 14m is lower than Q1 2024 but much higher than recent quarters. Also revenue trend negative, margins poor, expensive PE, no dividend. However, technical momentum is strong. Consensus signal deteriorating. Given my lens is SECTOR specialist focusing on fundamentals: low margins, declining revenue, negative operating cash flow, high leverage (liabilities to equity 7.99). The ROE is below cost of equity likely. So fundamentally weak. But the stock is cheap on book (0.68 PB) but that might be value trap. The recent capital raise and strategic investor may improve solvency, but near-term profitability still uncertain. Over 4-week horizon, the risk is that momentum fades after a 64% 3-month rally without fundamental support. So I lean towards HOLD. But we need to see if confidence is above 40. Given evidence conflicts: strong recent price momentum vs weak fundamentals, no clear catalyst. Confidence likely in 50-69 range (clear evidence with real conflicts). Since confidence below 40 would force HOLD anyway, but I think we can go HOLD with confidence maybe 50-60. Point: one sentence citing a figure. Could be: "SALAMA's net margin narrowed to 1.1% in FY2025, and operating cash flow was -AED57.8m." Risk: "The recent 64% 3-month rally lacks fundamental support, and the absence of near-term catalysts could trigger profit-taking." Stance: HOLD. Confidence: say 55. Target: null, because horizon is short and no catalyst to project price. But if we derive a target, we could use maybe technical or a conservative multiple, but with low confidence, better leave null. Citations: need at least 2 for non-HOLD, but HOLD doesn't require that? The instruction says "non-HOLD stances need at least 2." For HOLD, can be fewer, but we'll still cite evidence. I'll cite: - financial_statements.annual.0.net_margin_pct, value 1.1 (or fundamentals.net_margin? but annual shows 1.1). The fundamental net_margin is 1.4676, but that's TTM maybe. I'll use the annual 2025 net margin: financial_statements.annual.0.net_margin_pct: 1.1. - financial_statements.annual.0.ocf: -57.8. - indicators.ret_3m_pct: 64.1619. - recent_news.0 which is about Q1 2026 profit, but that's a headline, not a figure from the pack's structured fields. Could cite the date: recent_news.0.date: "2026-05-19". But better to cite a numeric figure: maybe fundamentals.rev_growth_yoy: -10.5117 to highlight revenue decline. I'll choose: financial_statements.annual.0.net_margin_pct: 1.1 and financial_statements.annual.0.ocf: -57.8. Also maybe fundamentals.pe_ttm: 30.5376 to show overvaluation vs peers. That's three cited figures aligning on weak fundamentals. So confidence can be 65 or so? But then the conflict is the strong recent momentum and Q1 profit. So confidence in 50-69 is appropriate. Thus, output: { "citations": [ {"field":"financial_statements.annual.0.net_margin_pct","value":1.1}, {"field":"financial_statements.annual.0.ocf","value":-57.8}, {"field":"fundamentals.pe_ttm","value":30.5376} ], "point": "SALAMA's FY2025 net margin contracted to 1.1% with negative operating cash flow of AED -57.8M, while trading at an elevated 30.5x P/E.", "risk": "The 64% 3-month surge may reverse without a near-term catalyst, given deteriorating fundamentals.", "stance": "HOLD", "confidence": 60, "target": null } Confidence 60 is within 50-69, clear evidence with real conflicts. The conflict is the Q1 2026 profit improvement and strong momentum, but fundamentally weak. So that's sound.

We are asked: "You are the TECHNICAL lens — trend (MA50 vs MA200, price vs MA200), momentum, vol, drawdown/gap structure (indicators), rel-strength vs DFMGI; if corporate_actions.upcoming_ex_date is present, treat the ex-date drop as mechanical, not a signal, one lens in a DFM equity-research panel rating SALAMA (Islamic Arab Insurance Co. (Salama) PJSC). Reason ONLY over this evidence pack; cite exact figures. Today is 2026-07-20; your stance covers ONLY the 4-week horizon ending 2026-08-17 — longer-term views belong in 'point', not the stance." We need to output a JSON with keys in order: citations, point, risk, stance, confidence, target. As the technical lens, we focus on technical indicators: trend (MA50 vs MA200, price vs MA200), momentum, vol, drawdown/gap structure, relative strength vs DFMGI. We ignore fundamentals, but we can cite specific technical fields from the pack. From pack: spot: 0.852 indicators: ma50: 0.733 ma200: 0.5595 pct_vs_ma200: 52.2843 ret_1m_pct: 14.9798 ret_3m_pct: 64.1619 ret_12m_pct: 115.1515 rel_strength_3m_vs_dfmgi_pct: 58.9798 rsi14: 64.6219 realized_vol_annual_pct: 50.2632 max_drawdown_1y_pct: -42.0455 pct_off_20d_high: -3.1818 atr14_pct_of_price: 3.5966 largest_gap_3m_pct: 5.6836 pct_no_trade_days_3m: 6.25 tv_technicals: tv_recommend_all: 0.2424 tv_recommend_ma: 0.6667 tv_recommend_other: -0.1818 adx: 52.2857 cci20: 63.6103 stoch_k: 59.7733 williams_r: -47.7941 high_52w: 0.928 low_52w: 0.491 rel_volume: 0.1215 volatility_d: 2.7155 beta_1y: 0.8101 dfmgi_context: dfmgi_ret_1m_pct: -5.958 dfmgi_ret_3m_pct: -1.1938 dfmgi_pct_vs_ma200: -3.5453 The horizon is 4 weeks ending 2026-08-17. We need to assess the technical picture for that short-term period. Technical analysis: - Price (0.852) is well above both MA50 (0.733) and MA200 (0.5595), so short-term and long-term trends are up. - Price vs MA200: 52.28% above MA200, indicating strong bullish trend. - MA50 (0.733) > MA200 (0.5595), golden cross, bullish. - RSI14: 64.62, approaching overbought but not yet extreme (above 70). Still room to run but with caution. - ADX: 52.29, strong trend strength. - Stoch K: 59.77, neutral. - Williams %R: -47.79, neutral. - CCI20: 63.61, neutral to slightly bullish. - Ret 1m: +14.98%, strong short-term momentum. - Ret 3m: +64.16%, very strong. - Volatility: realized vol 50.26% annual, high; daily vol 2.72%, high. So it's a volatile stock. - Max drawdown 1y: -42.05%, notable. - Relative strength vs DFMGI: +58.98% over 3 months, significantly outperforming the market (DFMGI 3m ret -1.19%). - The market context: DFMGI is below its 200-day MA (-3.55%) and has negative returns recently, while SALAMA is strongly outperforming. - Gaps: largest gap 3m 5.68%, pct no trade days 3m 6.25% indicates some illiquidity? But ADV 5.1m AED, moderate. For the 4-week horizon: The stock has strong momentum, but it's extended. RSI not overbought yet, but after such a big run, there could be a pullback or consolidation. However, the trend is strong, and relative strength is exceptional. No corporate actions upcoming (history only past dividends, no upcoming ex-date mentioned). So we treat it as pure technical. We need to output a stance: BUY, HOLD, or SELL. For technical, strong uptrend suggests BUY. But with high volatility and overbought risk, maybe a cautious BUY? Confidence: we need to assign a confidence band. Instructions: - 90-100 = multiple independent cited figures align AND a dated catalyst inside the horizon. - 70-89 = several aligned cited figures, no dated catalyst. - 50-69 = clear evidence with real conflicts. - 30-49 = mixed or one-sided evidence. - 10-29 = thin, stale, or gap-ridden evidence. - output HOLD below 40. Here, we have several aligned technical figures (MA crossover, price above MAs, strong momentum, strong relative strength). No dated catalyst in the horizon from the pack (no upcoming events in the 4-week period). So confidence would be 70-89. But we should check if there are any conflicts: RSI not overbought, but ADX high, volume relative low (rel_volume 0.1215 indicates low volume relative to average? Actually rel_volume is TV's relative volume, 0.12 means volume is 12% of average? That could be low). There's high volatility and a recent large drawdown. Some conflict: low relative volume suggests the recent move might lack volume support. But overall, the trend is strong. So "clear evidence with real conflicts"? Conflicts: RSI elevated but not extreme, low relative volume, high volatility. That could be 50-69. However, the instructions: "70-89 = several aligned cited figures, no dated catalyst." We have several aligned figures: price > MA50 > MA200, strong relative strength, positive momentum. Are there real conflicts? The conflicts: low rel_volume, high volatility, and RSI approaching overbought. These could be considered conflicts. I'd say the evidence is clearly bullish but with some caution, so maybe confidence 65? But the band for 70-89 says "no dated catalyst." We have no dated catalyst. I think the conflicts are not huge; they are typical of a strong trending stock. I'll lean to confidence 75, as several indicators align. But to be safe, let's see the exact wording: "several aligned cited figures, no dated catalyst" qualifies for 70-89. We have many aligned figures, so 75 is reasonable. Stance: BUY. The alternative could be HOLD if we think the stock is overextended and due for a pullback in the next 4 weeks. But the technical trend is strong, and we are only rating the 4-week horizon. The stock has strong momentum; pullbacks are possible, but the trend is likely to continue. I'll say BUY. Target: derive from pack evidence for 4-week horizon. Not analyst target (none anyway). We could project using ATR or recent momentum. ATR14 is 3.6% of price, so a 1-ATR move would be about 0.03. But we need a realistic 4-week target. Using momentum: 1-month return 14.98%, annualized high. We can't just project that. Perhaps use the 20-day high: pct_off_20d_high -3.18%, so the 20-day high is 0.852 / (1 - 0.031818) ≈ 0.88. That could be a near-term resistance. But we are bullish, so target could be maybe 0.92 or 0.93, near 52-week high of 0.928. But we need a derived target from pack evidence. Let's say based on ATR: 0.852 + (ATR14 * some multiple)? ATR14 pct is 3.5966%, so ATR in price is 0.852 * 0.035966 ≈ 0.0306. Over 4 weeks, typical move could be around 2-3 ATR? That gives 0.03 * 2 = 0.06, so target 0.91. Or using MA50 slope? Not provided. Alternatively, we could not provide a target if not confident. But the field says "num_or_null". I can set null if I don't have a clear derived target. But the instructions: "If you output a target, derive it from pack evidence for the 4-week horizon — do not restate analyst.target_mean." I could output null. I think it's safer to output null, as projecting price targets from technicals is speculative. But I can also give a target based on resistance. Let's see: 52-week high is 0.928, pct_below_52w_high is 8.19% from spot? Actually pct_below_52w_high is 8.1897, which means (high - spot)/high? Typically it's (high - current) / high? If spot 0.852, high 0.928, that's (0.928-0.852)/0.928 = 8.19%, yes. So it's 8.19% below the high. A 4-week target could be to retest that high. That would be a 8.19% gain. Given the strong momentum, that's plausible. But is that from pack evidence? The pack gives pct_below_52w_high, so I can compute target = high_52w * 0.928. So target 0.928. That is a clear figure: tv_technicals.high_52w = 0.928. So I'll set target: 0.928. Derivation: based on the stock's 52-week high, which could be reached in the strong uptrend. But should I cite it? I can cite high_52w. Now, citations: we need at least 2 for non-HOLD. List exact pack fields with dotted paths and values. Possible citations: - Trend: price vs MA200: indicators.pct_vs_ma200 = 52.2843 - Momentum: indicators.ret_1m_pct = 14.9798 - Relative strength: indicators.rel_strength_3m_vs_dfmgi_pct = 58.9798 - MA crossover: indicators.ma50 > indicators.ma200? We can cite the values: indicators.ma50 = 0.733, indicators.ma200 = 0.5595 - RSI: indicators.rsi14 = 64.6219 (not overbought) - ADX: tv_technicals.adx = 52.2857 (strong trend) - Volume: tv_technicals.rel_volume = 0.1215 (low) - For target: tv_technicals.high_52w = 0.928 - Also dfmgi_context.dfmgi_ret_1m_pct = -5.958 for relative outperformance. I'll choose a few that support the BUY stance. Point: one sentence citing a figure. Example: "SALAMA trades 52.3% above its 200-day MA with a 15% 1-month return and strong ADX of 52.3, indicating robust bullish momentum." Risk: one line, e.g., "High realized volatility (50.3% annual) and low relative volume (0.12) could lead to sudden pullbacks." Stance: BUY Confidence: 75 (since several aligned figures, no dated catalyst, but some conflicts like low volume and high volatility) Target: 0.928 (52-week high) Citations: I'll include dotted paths and values. Since the fields are from the pack, I'll use exact paths. Let's list citations: - indicators.pct_vs_ma200: 52.2843 - indicators.ret_1m_pct: 14.9798 - tv_technicals.adx: 52.2857 - indicators.rel_strength_3m_vs_dfmgi_pct: 58.9798 - tv_technicals.high_52w: 0.928 (for target) - indicators.ma50: 0.733, indicators.ma200: 0.5595 (for MA crossover) But we need at least 2 citations. I'll include a few to justify. Now, output JSON. Ensure order: citations, point, risk, stance, confidence, target. I'll format citations as an array of objects with field and value. Let's construct.

We are the VALUATION lens. We need to assess multiples vs fair value, dividend support, analyst consensus drift, and output a stance for the 4-week horizon ending 2026-08-17. First, extract key figures from the pack: - Spot price: 0.852 (likely AED) - Fundamentals: PE TTM 30.54, PB 0.68, PS 0.34, dividend yield 0.0 - Financials: Most recent annual (2025): revenue 1005M AED, net income 11.2M, OCF -57.8M, FCF -59.6M, equity 360M, liabilities/equity 7.99, net margin 1.1% - Quarterly: Q4 2025 (derived): revenue 236.3M, net income 0.1M; Q3 2025: rev 253.4M, NI 2.8M; Q2 2025: rev 259M, NI 7.9M - Peer context: median PE 11.32, median PB 1.35, median div yield 4.55%. SALAMA PE is 30.54 (89th percentile in a universe of 61), PB 0.68 (below median). - Dividend: yield 0%, no recent dividend (last declared 2022). corporate_actions: only 2022, 2021, 2020 dividends. So dividend support is absent. - FCF margin: derived fcf_margin_pct -5.9% (negative). OCF to NI: -5.16, so earnings quality is poor. - Analyst consensus: none (n: null, rec: "none"). consensus_signal_drift: tv_recommend_all 0.2424 (slightly positive), but drift: delta_5d -.294, delta_10d -.361, indicating recent deterioration in technical consensus. - Technicals: RSI 14: 64.62 (near overbought), price vs MA200: +52.28% (well above), ret_1m: +15%, ret_3m: +64%, realized vol 50% (high). tv_technicals recommend_all 0.2424, recommend_ma 0.6667, recommend_other -0.1818. - Macro: VIX 16.73 (moderate), rates elevated. Valuation lens: PE 30.5 vs median 11.3, making it very expensive relative to peers. PB 0.68 is low, but that might reflect weak profitability (ROE 4.3% vs median? not given but likely). PS 0.34. But earnings are minimal and volatile. The PE is distorted because net income is low and might have one-time items. FCF is negative, OCF negative, so no dividend support. The company hasn't paid dividends since 2022. The recent Q1 2026 news: "SALAMA reports net profit of AED 14 mn in Q1 2026" from recent_news on 2026-05-19. That suggests improvement. But still, Q1 net profit of 14M annualizes to 56M, which would give a forward PE of about 701M market cap / 56M = 12.5, closer to peer median. But that's not in the pack's derived fundamentals yet. However, we can use the evidence: recent_disclosures includes Q1 2026 results from 2026-05-18, but the financial statements in the pack only go up to 2025 Q4. The quarterly data we have is up to 2025-12-31. So we don't have the actual Q1 2026 financials, just the news headline. But we can consider the news as part of evidence. From a valuation perspective: The current PE of 30.5 is high. The book value is low (PB 0.68), but with negative FCF and high liabilities (liabilities/equity 7.99), the equity might be of questionable quality. The company has a history of volatile earnings. The latest annual net income is only 11.2M on revenue 1005M, margins razor-thin. Given the high PE, expensive relative to peers, no dividends, and negative FCF, the valuation lens would likely be bearish. However, the recent Q1 2026 profit of 14M (if sustainable) could lower the forward PE. But the consensus signal drift is negative, suggesting declining analyst/technical sentiment. The technicals show the stock has run up significantly (up 64% in 3 months) and RSI nearing overbought. This might indicate overvaluation in the short term. The horizon is 4 weeks. Are there any catalysts? The pack shows recent disclosures: board leadership appointments, BOD meetings, results of general assembly, etc. But no specific dated catalyst within the horizon. There is a Q1 2026 result already released on 2026-05-18. So no upcoming earnings within the horizon. No dividends expected. The only potential catalyst could be further news on the capital raise or strategic moves, but nothing dated. Given the valuation lens, the stock appears overvalued on trailing PE, with no dividend support, and recent price surge might be due for a pullback. The negative consensus drift supports that. So stance should be SELL or at least HOLD. Confidence might be moderate: we have multiple figures (expensive PE, negative FCF, no dividend) but no firm catalyst. Confidence band: 50-69? Let's see: we have clear evidence of overvaluation (PE 30.5 vs peers 11.3, negative FCF, no dividend) but conflicts: low PB, recent profit improvement, and technical momentum positive (strong returns). So conflicts exist. Confidence 60? But think: we need at least 2 citations. We'll cite PE and dividend yield, plus maybe FCF margin. Point: something like "SALAMA trades at a P/E of 30.5x vs peer median 11.3x with no dividend support and negative FCF margin of -5.9%, suggesting overvaluation." Risk: "The recent Q1 2026 profit of AED14mn could indicate a turnaround, reducing forward multiples." Stance: SELL, confidence: 65? But confidence: 50-69 requires "clear evidence with real conflicts". Yes. Target: we need to derive a target for 4-week horizon. If overvalued, what pullback? Recent price 0.852. Indicators: pct_off_20d_high: -3.18%, so high around 0.88. RSI 64, not extremely overbought. Could target say 0.80? Or perhaps we don't need a precise target? The instruction: "If you output a target, derive it from pack evidence for the 4-week horizon". We could look at support like MA200 at 0.5595, but that's far. Pct_vs_ma200 is 52%, so room to fall. But given limited horizon, maybe a target near 0.78? That would be about -8.5% from current. Not sure. Since there is no strong catalyst, maybe the stock could drift down. But I'd rather not force a target. We can output null for target if we can't derive a reasonable one. The instruction says: "do not restate analyst.target_mean (a 12-month figure) as your own target." It doesn't require a target; we can output null. In this case, I'll output null. Confidence: I'll go with 60. Now structure JSON: { "citations": [ {"field": "fundamentals.pe_ttm", "value": 30.5376}, {"field": "peer_context.median_pe_ttm", "value": 11.32}, {"field": "fundamentals.dividend_yield", "value": 0.0}, {"field": "financial_statements.derived.fcf_margin_pct", "value": -5.9} ], "point": "SALAMA trades at 30.5x trailing earnings versus a peer median of 11.3x, offers no dividend, and has a negative FCF margin of -5.9%, making it overvalued.", "risk": "A reported Q1 2026 net profit of AED14mn could signal a turnaround, potentially lowering forward multiples.", "stance": "SELL", "confidence": 60, "target": null } Check: citations use dotted paths, values as read. Good. We have 4 citations, >2. No fabricated catalyst. Stance is SELL. Confidence 60, which is in 50-69 band. No target output. Now ensure JSON only, no other text.